ArticleEmerging infectious diseases2020
Clostridioides difficile in COVID-19 Patients, Detroit, Michigan, USA, March-April 2020.
Article in Emerging infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The burden of Clostridioides difficile infection in COVID-19 patients: A systematic review and meta-analysis.Anaerobe · 2022Pooled it
- Diagnostic, Prognostic, and Therapeutic Roles of Gut Microbiota in COVID-19: A Comprehensive Systematic Review.Frontiers in cellular and infection microbiology · 2022Pooled it
- Clostridioides difficile Infection in Patients with Chronic Kidney Disease: A Systematic Review.BioMed research international · 2021Pooled it
- Article
- Oral Vancomycin in the Treatment ofAntibiotics (Basel, Switzerland) · 2026Article
- Article
- Understanding host immune responses iniMeta · 2024Review
- COVID-19 andAntibiotics (Basel, Switzerland) · 2024Article
- Molecular docking, dynamics andBioinformation · 2024Article
- Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Symptoms, Treatment, and Outcomes of COVID-19 Patients Coinfected withAntibiotics (Basel, Switzerland) · 2023Article
- Article
- Clostridium difficile Infection Rates During the Pandemic in New York Capital Area: A Single-Center Study.Cureus · 2023Article
- The burden of CDI in the United States: a multifactorial challenge.BMC infectious diseases · 2023Review
- The impact of the COVID-19 pandemic onTherapeutic advances in gastroenterology · 2023Review
- Fecal Microbiota Transplantation in Patients Co-Infected with SARS-CoV2 andBiomedicines · 2022Article
- The Impact of Clostridioides Difficile Infection in Hospitalized Patients: What Changed during the Pandemic?Diagnostics (Basel, Switzerland) · 2022Article
- Comparison between Symptomatic and Asymptomatic Mice afterMicroorganisms · 2022Article
- Article
- Clinical Presentations, Predictive Factors, and Outcomes of Clostridioides difficile Infection among COVID-19 Hospitalized Patients—A Single Center Experience from the COVID Hospital of the University Clinical Center of Vojvodina, SerbiaMedicina (Kaunas, Lithuania) · 2022Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe 9 patients at a medical center in Detroit, Michigan, USA, with severe acute respiratory syndrome coronavirus 2 and Clostridioides difficile. Both infections can manifest as digestive symptoms and merit screening when assessing patients with diarrhea during the coronavirus disease pandemic. These co-infections also highlight the continued importance of antimicrobial stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.